Skip to main content
. 2021 Feb 22;12:1222. doi: 10.1038/s41467-021-21410-1

Fig. 3. PD-L1 targeting in mouse model for colorectal cancer.

Fig. 3

a Tumor growth of PD-1/PD-L1 humanized mice implanted with MC38 cells expressing humanized PD-L1 and treated with compound A (10 mg/kg orally for seven daily doses days 0–6), or αPD-L1 (10 mg/kg intraperitoneal injection thrice weekly days 0–16). Statistically significant tumor growth inhibition was observed with αPD-L1 antibody or compound A treatment (p < 0.0001 or p = 0.009, respectively, group means comparison relative to vehicle by one-way ANOVA with Dunnett’s multiple comparisons test). b Compound A treatment mediates decrease in tumor PD-L1 expression at day 28. **p = 0.002 by unpaired t test. NC data not collected due to insufficient tumor amounts for analysis. c Tumor inhibition is directly correlated with the degree of tumor PD-L1 reduction. d–f Counts of CD3+ cells in blood at day 28, with further gating for CD4+ or CD8+ cells. g Frequency of T regulatory cells in blood. *p = 0.03, **p = 0.003, ***p = 0.0002, ****p < 0.0001 by one-Way ANOVA with Dunnett’s multiple comparisons test. Source data are provided as a Source data file.